Menu

Google, Novartis to Develop Smart Contacts

The technologically advanced eyewear monitors blood sugar concentrations in diabetic patients.

Jul 17, 2014
Bob Grant

GOOGLEInternet giant Google and pharmaceutical company Novartis are joining forces to develop a high-tech contact lens that will be able to monitor blood sugar levels in people with diabetes, Novartis announced in a statement released Tuesday (July 15).

Google announced the creation of a prototype of the smart lens in January. “We’re now testing a smart contact lens that’s built to measure glucose levels in tears using a tiny wireless chip and miniaturized glucose sensor that are embedded between two layers of soft contact lens material,” the company said in a January 16 post on its official blog. “We’re testing prototypes that can generate a reading once per second.”

Six months later, Alcon, Novartis’s eye care unit, has licensed the technology from GoogleX, the research division within the Internet company that tackles global technological problems, with the goal of pushing the smart lens onto the market. “We are looking forward to working with Google to bring together their advanced technology and our extensive knowledge of biology to meet unmet medical needs,” Novartis CEO Joseph Jimenez said in the statement. “This is a key step for us to go beyond the confines of traditional disease management, starting with the eye.”

Blood glucose concentrations could be sent from tiny sensors via a super thin radio antenna in the contact lenses to a doctor’s or a wearer’s computer or smart phone to alert them to dangerously rising or falling levels.

“If it is accurate and affordable, it could be an absolute game-changer,” dietician and diabetes expert Jill Weisenberger told the Los Angeles Times. More than 29 million Americans have diabetes, according to the American Diabetes Association.

Jimenez declined to tell The New York Times the financial terms of the deal, nor did he give an estimate for what the lenses might cost.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!